MedTrace Logo

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

NCT02283294 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2021-11-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.

Conditions

Interventions

DRUG

Apixaban

DRUG

Warfarin

Sponsors & Collaborators

Principal Investigators

  • Michael Fradley, M.D. · University of South Florida, Department of Cardiovascular Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02283294 on ClinicalTrials.gov